A 32-year-old man from Delhi presents to the de-addiction centre with a 6-year history of heroin use. He reports using 2–3 grams daily via inhalation ('chasing the dragon'). For the past 48 hours, he has experienced severe muscle aches, insomnia, anxiety, lacrimation, rhinorrhea, and diarrhea. Vital signs: HR 102 bpm, BP 138/88 mmHg, temperature 37.8°C. He is restless and diaphoretic. What is the most appropriate immediate pharmacological intervention?

Explanation

## Acute Opioid Withdrawal Management **Key Point:** Buprenorphine is the first-line agent for opioid withdrawal in most clinical settings, especially in primary care and de-addiction centres in India. It combines partial μ-opioid agonism with κ-antagonism, providing symptom relief while minimizing overdose risk. ### Why Buprenorphine is Preferred Here 1. **Partial agonist profile** — reduces withdrawal symptoms without producing euphoria, lowering abuse potential 2. **Ceiling effect on respiratory depression** — safer in overdose than full agonists like methadone 3. **Sublingual formulation** — rapid onset (20–40 minutes), suitable for acute withdrawal 4. **Tapering flexibility** — can be withdrawn over 7–14 days with minimal rebound symptoms 5. **Lower diversion risk** — less attractive on the street than methadone ### Clinical Pearl **High-Yield:** In acute opioid withdrawal, the goal is symptom management, not complete abstinence induction. Buprenorphine 8 mg sublingual daily (may be split into 4 mg BD) is initiated on day 1 and tapered by 2 mg every 2–3 days. This patient's signs (tachycardia, diaphoresis, muscle aches, diarrhea, lacrimation) are classic withdrawal—not overdose—and warrant opioid replacement, not antagonism. ### Comparison Table: Opioid Withdrawal Management Agents | Agent | Mechanism | Onset | Abuse Potential | Respiratory Risk | Tapering Duration | |-------|-----------|-------|-----------------|------------------|-------------------| | **Buprenorphine** | Partial μ-agonist | 20–40 min | Low | Very low (ceiling) | 7–14 days | | **Methadone** | Full μ-agonist | 30–60 min | Moderate–High | High (no ceiling) | 10–21 days | | **Naltrexone** | μ-antagonist | 30 min | None | None | N/A | | **Clonidine** | α~2~-agonist | 30–60 min | None | None | 7–10 days | **Warning:** Naltrexone (option 3) is contraindicated in acute withdrawal—it precipitates severe, potentially life-threatening withdrawal by blocking residual opioid effects. Diazepam alone (option 4) does not address the underlying opioid deficiency and risks benzodiazepine dependence. ### Mnemonic: BUPE for Buprenorphine **B** — **Begins** withdrawal relief in 20–40 minutes **U** — **Useful** in primary care and outpatient settings **P** — **Partial** agonist = lower overdose risk **E** — **Easy** tapering with minimal rebound [cite:Harrison 21e Ch 474]